Medicine and Dentistry
Prostate Cancer
90%
Kidney Metastasis
74%
Clear Cell Renal Cell Carcinoma
57%
Neoplasm
49%
Overall Survival
40%
Progression Free Survival
40%
Clinical Trial
32%
Circulating Tumor DNA
31%
Malignant Neoplasm
30%
Diseases
27%
Immunity
27%
Cabozantinib
25%
Targeted Therapy
24%
Immune Checkpoint Inhibitor
23%
Next Generation Sequencing
23%
Transitional Cell Carcinoma
20%
Castration Resistant Prostate Cancer
20%
Androgen Receptor
20%
Cancer
18%
Immunotherapy
17%
Sarcomatoid
16%
Apalutamide
16%
Prostatectomy
13%
Cell Dedifferentiation
13%
Body Mass Index
13%
Metastatic Carcinoma
13%
Biological Marker
12%
Abiraterone Acetate
12%
Phase II Trials
12%
Network Meta-Analysis
12%
Interleukin 2
12%
Oncology
12%
Neutrophil
12%
Lymphocyte
12%
Cell-Free DNA
11%
Radiation Therapy
11%
Adverse Event
11%
Penis Cancer
11%
Prednisone
11%
Drug Megadose
11%
Systematic Review
11%
Hormone Therapy
11%
Germ Cell
10%
Pembrolizumab
10%
Clear Cell
10%
Tyrosine-Kinase Inhibitor
10%
Androgen
10%
Somatics
9%
Lenvatinib
9%
Squamous Cell Carcinoma
9%
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
62%
Circulating Tumor DNA (ctDNA)
35%
Renal Cell Carcinoma
34%
Enzalutamide
33%
Progression-free Survival
33%
Overall Survival
30%
Prostate Cancer
29%
Immune Checkpoint Inhibitors
24%
Immune Checkpoint Therapy
23%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
23%
Tumor
21%
Next-generation Sequencing
20%
Metastatic Urothelial Carcinoma
19%
MD Anderson Cancer Center
19%
Genetic Modification
19%
Targeted Therapy
18%
Androgen Signaling
17%
Sarcomatoid
16%
Phase I Study
16%
Obesity
16%
Rhabdoid
16%
Castration-resistant Prostate Cancer
16%
Confidence Interval
16%
Prednisone
16%
Abiraterone Acetate
16%
Cabozantinib
16%
Cell-free DNA (cfDNA)
15%
Clear Cell Renal Cell Carcinoma (ccRCC)
15%
Androgen Receptor
14%
Apalutamide
14%
Dedifferentiation
14%
Androgen Deprivation Therapy
14%
Older Patients
14%
Body Mass Index
14%
Tumor Tissue
13%
Phase II Trial
13%
Radical Prostatectomy
13%
Abiraterone
13%
Clinical Outcomes
13%
Systemic Therapy
13%
Body Composition
13%
Glucocorticoid Receptor
12%
Tolerability
12%
Survival Outcomes
12%
Intermediate-risk Prostate Cancer
12%
Network Meta-analysis
12%
Programmed Death-ligand 1 (PD-L1)
12%
High-dose interleukin-2
11%
Molecular Predictors
11%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
79%
Prostate Cancer
64%
Castration Resistant Prostate Cancer
60%
Renal Cell Carcinoma
59%
Progression Free Survival
59%
Overall Survival
51%
Neoplasm
47%
Circulating Tumor DNA
31%
Clinical Trial
31%
Malignant Neoplasm
29%
Diseases
29%
Enzalutamide
29%
Cabozantinib
28%
Prednisone
23%
Abiraterone Acetate
22%
Androgen
20%
Vasculotropin
19%
Protein Tyrosine Kinase Inhibitor
18%
Immune Checkpoint Inhibitor
17%
Immunotherapy
17%
Biological Marker
14%
Ipilimumab
14%
Interleukin 2
14%
Abiraterone
13%
Androgen Receptor
13%
Nivolumab
13%
Tolerability
12%
Transitional Cell Carcinoma
10%
Protein Tyrosine Kinase
10%
Lenvatinib
9%
Everolimus
9%
Adverse Event
9%
Vasculotropin Receptor
8%
Carboplatin
8%
Combination Therapy
8%
Apalutamide
7%
Metastasis
6%
Bladder Cancer
6%
Kidney Cancer
6%
Retrospective Study
6%
Fibroblast Growth Factor Receptor 3
6%
Phase I Trials
6%
Disease Exacerbation
6%
Sunitinib
5%
Disease Marker
5%
Eplerenone
5%
Programmed Death 1 Ligand 1
5%
Tivozanib
5%
Glucocorticoid Receptor Antagonist
5%
Sapanisertib
5%